NEU_INTERSTIM_INS
Report
- Report Number
- 3007566237-2017-05333
- Event Type
- Injury
- Date Received
- December 28, 2017
- Date of Event
- July 13, 2017
- Report Date
- July 3, 2018
- Manufacturer
- MEDTRONIC NEUROMODULATION
- Product Code
- EZW
- PMA / PMN Number
- P080025
- Adverse Event
- Yes
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- US
- Reporter Occupation
- OTHER
Narratives
PLEASE NOTE THAT THIS DATE IS BASED OFF OF THE DATE OF PUBLICATION OF THE ARTICLE AS THE EVENT DATES WERE NOT PROVIDED IN THE PUBLISHED LITERATURE.
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
LAGARES-TENA, L., MUNOZ-DUYOS, A. USE OF A NEW PLASMA SCALPEL DURING PULSE GENERATOR IMPLANT AND REPLACEMENT IN NEUROMODULATION. COGENT MEDICINE. 2017. 4: 1353248. DOI: 10.1080/2331205X.2017.1353248 SUMMARY: SACRAL NEUROMODULATION (SNM) IS A MINIMALLY INVASIVE THERAPY FOR DEFECATORY DISORDERS. PEAK PLASMA BLADE¿ (MEDTRONIC) HAS BEEN USED AS AN ALTERNATIVE TO THE CONVENTIONAL ELECTRIC SCALPEL AND SCISSORS IN 3 PROCEDURES OF NEUROMODULATION. PEAK PLASMABLADE¿ USES LESS TOTAL ENERGY, OPERATING AT SIGNIFICANTLY LOWER TEMPERATURES THAN ELECTROSURGICAL TECHNOLOGY. NO DAMAGE TO THE WIRES OR PULSE GENERATORS OR PATIENT COMPLICATIONS WERE DETECTED DURING THE SURGERY OR FOLLOW-UP. A REDUCTION IN THE DURATION OF THE PROCEDURES WAS NOTED. REPORTED EVENTS: A (B)(6) WOMAN WAS DIAGNOSED WITH SEVERE NEUROLOGIC FECAL INCONTINENCE. THE PATIENT WAS IMPLANTED AFTER A SUCCESSFUL TINED LEAD TEST IN 2010 IN THE LEFT S3 NERVE ROOT. AFTER FIVE YEARS, THE PATIENT REFERRED A RELAPSE IN HER SYMPTOMS. LOW BATTERY LEVEL WAS DETECTED AND A PG EXCHANGE WAS PERFORMED. NO SPECIFIC DEVICE INFORMATION PROVIDED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 930913 | NEU_INTERSTIM_INS | STIMULATOR, ELECTRICAL, IMPLANTABLE, FOR INCONTINENCE | EZW | MEDTRONIC NEUROMODULATION | NEU_INTERSTIM_INS | UNKNOWN |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 51 YR | Required Intervention |